{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:27:03Z","timestamp":1793320023615,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004334","name":"Etel\u00e4-Pohjanmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["6107"],"award-info":[{"award-number":["6107"]}],"id":[{"id":"10.13039\/501100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008723","name":"Suomen L\u00e4\u00e4ketieteen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010125","name":"Jalmari ja Rauha Ahokkaan S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Foundation for Psychiatric Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Poor adherence and negative attitudes to treatment are common clinical problems when treating psychotic disorders. This study investigated how schizophrenia core symptoms and daily functioning affect treatment adherence and attitudes toward antipsychotic medication and to compare patients using clozapine or other antipsychotics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A cross-sectional study with data from 275 patients diagnosed with schizophrenia spectrum disorder. Patients adherence, attitudes, insight and side-effects were evaluated using the Attitudes toward Neuroleptic Treatment scale. Overall symptomology was measured using the Brief Psychiatric Rating Scale (BPRS), the Health of the Nation Outcome Scale (HoNOS). The functioning was assessed using activities of daily living scale, instrumental activities of daily living scale and social functioning of daily living scale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Self-reported treatment adherence was high. Of the patients, 83% reported using at least 75% of the prescribed medication. Having more symptoms was related with more negative attitude towards treatment. There was a modest association with functioning and treatment adherence and attitude toward antipsychotic treatment. Attitudes affected on adherence in non-clozapine but not in clozapine groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Early detection of non-adherence is difficult. Systematic evaluation of attitudes toward the treatment could be one way to assess this problem, along with optimized medication, prompt evaluation of side effects and flexible use of psychosocial treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03037-0","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T10:05:59Z","timestamp":1610532359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1542-3746","authenticated-orcid":false,"given":"J.","family":"Leijala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Kampman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Suvisaari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Eskelinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"issue":"3","key":"3037_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"3037_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S026418010000059X","volume":"15","author":"M Shepherd","year":"1989","unstructured":"Shepherd M, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl. 1989;15:1\u201346.","journal-title":"Psychol Med Monogr Suppl"},{"issue":"1","key":"3037_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-0447.1981.tb00761.x","volume":"64","author":"B Wistedt","year":"1981","unstructured":"Wistedt B. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand. 1981;64(1):65\u201384.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"3037_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1001\/jamapsychiatry.2014.2127","volume":"72","author":"TA Furukawa","year":"2015","unstructured":"Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry. 2015;72(1):14\u201321.","journal-title":"JAMA Psychiatry"},{"issue":"9831","key":"3037_CR5","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063\u201371.","journal-title":"Lancet"},{"issue":"2","key":"3037_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152\u201363.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"3037_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","volume":"175","author":"J Tiihonen","year":"2018","unstructured":"Tiihonen J, Tanskanen A, Taipale H. 20-year Nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry. 2018;175(8):765\u201373.","journal-title":"Am J Psychiatry"},{"key":"3037_CR8","doi-asserted-by":"publisher","first-page":"31-244X-8-31","DOI":"10.1186\/1471-244X-8-31","volume":"8","author":"E Johnsen","year":"2008","unstructured":"Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008;8:31-244X-8-31.","journal-title":"BMC Psychiatry"},{"issue":"10","key":"3037_CR9","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"3037_CR10","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/archpsyc.62.12.1305","volume":"62","author":"G Kemmler","year":"2005","unstructured":"Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62(12):1305\u201312.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 2","key":"3037_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4088\/JCP.9096su1cc.04","volume":"71","author":"DC Goff","year":"2010","unstructured":"Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010;71(Suppl 2):20\u20136.","journal-title":"J Clin Psychiatry"},{"key":"3037_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/PPA.S124658","volume":"11","author":"DI Velligan","year":"2017","unstructured":"Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449\u201368.","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"3037_CR13","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.euroneuro.2013.09.001","volume":"23","author":"C Brain","year":"2013","unstructured":"Brain C, Allerby K, Sameby B, Quinlan P, Joas E, Karilampi U, et al. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS((R))) in the Swedish COAST-study. Eur Neuropsychopharmacol. 2013;23(12):1754\u201362.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"3037_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eurpsy.2005.05.015","volume":"21","author":"M Kamali","year":"2006","unstructured":"Kamali M, Kelly BD, Clarke M, Browne S, Gervin M, Kinsella A, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry. 2006;21(1):29\u201333.","journal-title":"Eur Psychiatry"},{"issue":"10","key":"3037_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1017\/S0033291706007793","volume":"36","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS, et al. Insight in first-episode psychosis. Psychol Med. 2006;36(10):1385\u201393.","journal-title":"Psychol Med"},{"issue":"2","key":"3037_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/schbul\/sbn067","volume":"35","author":"S Mohamed","year":"2009","unstructured":"Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull. 2009;35(2):336\u201346.","journal-title":"Schizophr Bull"},{"issue":"2\u20133","key":"3037_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","volume":"176","author":"D Novick","year":"2010","unstructured":"Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2\u20133):109\u201313.","journal-title":"Psychiatry Res"},{"key":"3037_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12888-015-0560-4","volume":"15","author":"D Novick","year":"2015","unstructured":"Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry. 2015;15:189 015\u20130560-4.","journal-title":"BMC Psychiatry"},{"issue":"7","key":"3037_CR19","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.4088\/JCP.v67n0715","volume":"67","author":"H Ascher-Svanum","year":"2006","unstructured":"Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry. 2006;67(7):1114\u201323.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"3037_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","volume":"106","author":"EL Coldham","year":"2002","unstructured":"Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286\u201390.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"3037_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.schres.2005.10.016","volume":"83","author":"DO Perkins","year":"2006","unstructured":"Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83(1):53\u201363.","journal-title":"Schizophr Res"},{"issue":"9","key":"3037_CR22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.4088\/JCP.v65n0908","volume":"65","author":"MA Rettenbacher","year":"2004","unstructured":"Rettenbacher MA, Hofer A, Eder U, Hummer M, Kemmler G, Weiss EM, et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry. 2004;65(9):1211\u20138.","journal-title":"J Clin Psychiatry"},{"key":"3037_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-244X-12-20","volume":"12","author":"M Dibonaventura","year":"2012","unstructured":"Dibonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012;12:20 244X-12-20.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"3037_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/schbul\/sbs005","volume":"39","author":"S Moritz","year":"2013","unstructured":"Moritz S, Favrod J, Andreou C, Morrison AP, Bohn F, Veckenstedt R, et al. Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis. Schizophr Bull. 2013;39(4):917\u201322.","journal-title":"Schizophr Bull"},{"issue":"1","key":"3037_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/070674370905400106","volume":"54","author":"M Rabinovitch","year":"2009","unstructured":"Rabinovitch M, Bechard-Evans L, Schmitz N, Joober R, Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatr. 2009;54(1):28\u201335.","journal-title":"Can J Psychiatr"},{"issue":"9859","key":"3037_CR26","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2012","unstructured":"Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the global burden of disease study 2010. Lancet. 2012;380(9859):2129\u201343.","journal-title":"Lancet"},{"issue":"6","key":"3037_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.eurpsy.2010.12.005","volume":"27","author":"S Viertio","year":"2012","unstructured":"Viertio S, Tuulio-Henriksson A, Perala J, Saarni SI, Koskinen S, Sihvonen M, et al. Activities of daily living, social functioning and their determinants in persons with psychotic disorder. Eur Psychiatry. 2012;27(6):409\u201315.","journal-title":"Eur Psychiatry"},{"issue":"1\u20133","key":"3037_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2016.09.015","volume":"178","author":"L Samalin","year":"2016","unstructured":"Samalin L, de Chazeron I, Blanc O, Brunel L, Fond G, Llorca PM. Attitudes toward antipsychotic medications as a useful feature in exploring medication non-adherence in schizophrenia. Schizophr Res. 2016;178(1\u20133):1\u20135.","journal-title":"Schizophr Res"},{"issue":"7","key":"3037_CR29","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1176\/ajp.156.7.990","volume":"156","author":"K Wahlbeck","year":"1999","unstructured":"Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156(7):990\u20139.","journal-title":"Am J Psychiatry"},{"issue":"9896","key":"3037_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"issue":"1","key":"3037_CR31","doi-asserted-by":"publisher","first-page":"e013881","DOI":"10.1136\/bmjopen-2016-013881","volume":"7","author":"D Keating","year":"2017","unstructured":"Keating D, McWilliams S, Schneider I, Hynes C, Cousins G, Strawbridge J, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881 -2016-013881.","journal-title":"BMJ Open"},{"issue":"1","key":"3037_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/acps.12742","volume":"136","author":"CJ Bachmann","year":"2017","unstructured":"Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand. 2017;136(1):37\u201351.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"3037_CR33","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","volume":"44","author":"H Taipale","year":"2018","unstructured":"Taipale H, Mehtala J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for Rehospitalization in schizophrenia-a Nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381\u20137.","journal-title":"Schizophr Bull"},{"issue":"1","key":"3037_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JCP.0000000000000623","volume":"37","author":"HY Chan","year":"2017","unstructured":"Chan HY, Pan YJ, Chen JJ, Chen CH. Time to discontinuation of second-generation antipsychotics versus haloperidol and Sulpiride in people with schizophrenia: a naturalistic, Comparative Study. J Clin Psychopharmacol. 2017;37(1):13\u201320.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"3037_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/JCP.0000000000000597","volume":"36","author":"HC Ndukwe","year":"2016","unstructured":"Ndukwe HC, Nishtala PS. Time-to-first discontinuation, adherence and persistence in new users of second-generation antipsychotics. J Clin Psychopharmacol. 2016;36(6):649\u201357.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"3037_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/acps.12233","volume":"130","author":"MC Davis","year":"2014","unstructured":"Davis MC, Fuller MA, Strauss ME, Konicki PE, Jaskiw GE. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. Acta Psychiatr Scand. 2014;130(1):30\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"3037_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0920-9964(99)00204-2","volume":"45","author":"O Kampman","year":"2000","unstructured":"Kampman O, Lehtinen K, Lassila V, Leinonen E, Poutanen O, Koivisto A. Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. Schizophr Res. 2000;45(3):223\u201334.","journal-title":"Schizophr Res"},{"key":"3037_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1192\/bjp.172.1.11","volume":"172","author":"JK Wing","year":"1998","unstructured":"Wing JK, Beevor AS, Curtis RH, Park SB, Hadden S, Burns A. Health of the nation outcome scales (HoNOS). Research and development. Br J Psychiatry. 1998;172:11\u20138.","journal-title":"Br J Psychiatry"},{"key":"3037_CR39","first-page":"227","volume":"3","author":"J Ventura","year":"1993","unstructured":"Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green M, Shaner A. Brief Psychiatric Rating Scale (BPRS) Expanded version (4.0) scales, anchor points and administration manual. Int J Methods Psychiatr Res. 1993;3:227\u201344.","journal-title":"Int J Methods Psychiatr Res"},{"key":"3037_CR40","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.","edition":"4"},{"issue":"S7","key":"3037_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1192\/S0007125000291496","volume":"155","author":"NC Andreasen","year":"1989","unstructured":"Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry. 1989;155(S7):49\u201352.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"3037_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000111551","volume":"41","author":"A Kopelowicz","year":"2008","unstructured":"Kopelowicz A, Ventura J, Liberman RP, Mintz J. Consistency of brief psychiatric rating scale factor structure across a broad spectrum of schizophrenia patients. Psychopathology. 2008;41(2):77\u201384.","journal-title":"Psychopathology"},{"key":"3037_CR43","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","volume":"185","author":"S Katz","year":"1963","unstructured":"Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of Illness in the Aged the Index of Adl: a Standardized Measure of Biological and Psychosocial Function. JAMA. 1963;185:914\u20139.","journal-title":"JAMA"},{"issue":"3","key":"3037_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3):179\u201386.","journal-title":"Gerontologist"},{"issue":"4","key":"3037_CR45","first-page":"413","volume":"29","author":"JR McWhinnie","year":"1981","unstructured":"McWhinnie JR. Disability assessment in population surveys: results of the O.E.C.D. common development effort. Rev Epidemiol Sante Publique. 1981;29(4):413\u20139.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"3037_CR46","first-page":"187","volume-title":"Meyler\u2019s side effects of psychiatric drugs","author":"JK Aronson","year":"2009","unstructured":"Aronson JK. Meyler\u2019s side effects of psychiatric drugs. Amsterdam: Elsevier; 2009. p. 187."},{"issue":"6","key":"3037_CR47","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1080\/08039488.2017.1319497","volume":"71","author":"S Eskelinen","year":"2017","unstructured":"Eskelinen S, Sailas E, Joutsenniemi K, Holi M, Koskela TH, Suvisaari J. Multiple physical healthcare needs among outpatients with schizophrenia: findings from a health examination study. Nord J Psychiatry. 2017;71(6):448\u201354.","journal-title":"Nord J Psychiatry"},{"issue":"1","key":"3037_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12888-018-1737-4","volume":"18","author":"U Stentzel","year":"2018","unstructured":"Stentzel U, van den Berg N, Schulze LN, Schwaneberg T, Radicke F, Langosch JM, et al. Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla). BMC Psychiatry. 2018;18(1):155 -018-1737-4.","journal-title":"BMC Psychiatry"},{"issue":"7561","key":"3037_CR49","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/bmj.38881.382755.2F","volume":"333","author":"J Tiihonen","year":"2006","unstructured":"Tiihonen J, Wahlbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224.","journal-title":"BMJ"},{"issue":"3","key":"3037_CR50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.20060","volume":"12","author":"JM Kane","year":"2013","unstructured":"Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216\u201326.","journal-title":"World Psychiatry"},{"issue":"2","key":"3037_CR51","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/acps.13208","volume":"142","author":"H Takeuchi","year":"2020","unstructured":"Takeuchi H, Borlido C, Sanches M, Teo C, Harber L, Agid O, et al. Adherence to clozapine vs. other antipsychotics in schizophrenia. Acta Psychiatr Scand. 2020;142(2):87\u201395.","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"3037_CR52","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.euroneuro.2015.04.003","volume":"25","author":"P Czobor","year":"2015","unstructured":"Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol. 2015;25(8):1158\u201366.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"3037_CR53","doi-asserted-by":"publisher","first-page":"e1130","DOI":"10.4088\/JCP.15m10115","volume":"77","author":"D Misdrahi","year":"2016","unstructured":"Misdrahi D, Tessier A, Swendsen J, Berna F, Brunel L, Capdevielle D, et al. Determination of adherence profiles in schizophrenia using self-reported adherence: results from the FACE-SZ dataset. J Clin Psychiatry. 2016;77(9):e1130\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"3037_CR54","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1600-0447.2007.01087.x","volume":"116","author":"A Hofer","year":"2007","unstructured":"Hofer A, Rettenbacher MA, Edlinger M, Kemmler G, Widschwendter CG, Fleischhacker WW. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand. 2007;116(5):354\u201361.","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl 16","key":"3037_CR55","first-page":"10","volume":"64","author":"WW Fleischhacker","year":"2003","unstructured":"Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry. 2003;64(Suppl 16):10\u20133.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"3037_CR56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1034\/j.1600-0447.2000.102003203.x","volume":"102","author":"H Verdoux","year":"2000","unstructured":"Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000;102(3):203\u201310.","journal-title":"Acta Psychiatr Scand"},{"issue":"2\u20133","key":"3037_CR57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.schres.2008.09.007","volume":"107","author":"FJ Acosta","year":"2009","unstructured":"Acosta FJ, Bosch E, Sarmiento G, Juanes N, Caballero-Hidalgo A, Mayans T. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res. 2009;107(2\u20133):213\u20137.","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"3037_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.psychres.2004.11.002","volume":"133","author":"M Byerly","year":"2005","unstructured":"Byerly M, Fisher R, Whatley K, Holland R, Varghese F, Carmody T, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005;133(2\u20133):129\u201333.","journal-title":"Psychiatry Res"},{"issue":"2","key":"3037_CR59","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/17425247.2016.1115479","volume":"13","author":"T Suzuki","year":"2016","unstructured":"Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opin Drug Deliv. 2016;13(2):253\u201364.","journal-title":"Expert Opin Drug Deliv"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03037-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-021-03037-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03037-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T03:14:19Z","timestamp":1674875659000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03037-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3037"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03037-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa and by the Hyvink\u00e4\u00e4 Hospital Area. All participants gave a written informed consent<b>.<\/b>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Saana Eskelinen has received Speaker Honoraria from Lundbeck, Otsuka and Sunovion, and has been a consultant for Finnish Lung Health Association.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}